(187 days)
Not Found
No
The summary describes a standard laboratory immunoassay for measuring glycated hemoglobin and does not mention any AI or ML components.
No
The device is an in vitro diagnostic assay used for measuring glycated hemoglobin to manage diabetes mellitus, but it does not directly treat or provide therapy to patients.
Yes
The device measures glycated hemoglobin, which is used for the management of diabetes mellitus. This involves providing information used to diagnose, monitor, or predict a disease or health condition.
No
The device description clearly states it is a Chemiluminescent Microparticle Immunoassay (CMIA) and involves the use of the ARCHITECT™ i System, which are hardware components for performing the assay.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it's for measuring glycated hemoglobin in human anticoagulated whole blood for the management of diabetes mellitus. This is a diagnostic purpose performed in vitro (outside the body) on a biological sample.
- Device Description: It describes a Chemiluminescent Microparticle Immunoassay (CMIA) for the quantitative determination of glycated hemoglobin in human whole blood. This is a laboratory-based test performed on a sample.
- Performance Studies: The performance studies compare the device to a predicate device (Bio-Rad DIAMAT™ Glycosylated Hemoglobin Analyzer System) which is also an IVD for measuring glycated hemoglobin. This comparison is typical for demonstrating the performance of a new IVD.
- Predicate Device: The mention of a predicate device (K851636; Bio-Rad DIAMAT™ Glycosylated Hemoglobin Analyzer System) further confirms its classification as an IVD, as predicate devices are used for comparison in the regulatory submission process for new IVDs.
All these points align with the definition and characteristics of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The ARCHITECT™ Glycated Hemoglobin assay is a Chemiluminescent Microparticle Immunoassay (CMIA) for the quantitative determination of glycated hemoglobin in human anticoagulated whole blood (EDTA, lithium heparin, or sodium heparin).
The Abbott ARCHITECT™ Glycated Hemoglobin assay is a boronate affinity binding assay intended to measure glycated hemoglobin in human anticoagulated whole blood. Measurement of glycated hemoglobin is used for the management of diabetes mellitus.
Product codes
LCP
Device Description
The ARCHITECT™ Glycated Hemoglobin assay is a Chemiluminescent Microparticle Immunoassay (CMIA) for the quantitative determination of glycated hemoglobin in human anticoagulated whole blood (EDTA, lithium heparin, or sodium heparin). The ARCHITECTTM Glycated Hemoglobin assay is calibrated with Abbott ARCHITECT™ Glycated Hemoglobin Calibrators. Abbott ARCHITECT™ Glycated Hemoglobin Controls are assayed for the verification of the accuracy and precision of the Abbott ARCHITECT™ i System.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Not Found
Key Metrics
| Sample | Regression Method | n | r | Slope (95%CI) | Intercept (95% CI) |
|---|---|---|---|---|---|
| Whole Blood | Least Squares | 249 | 0.961 | 0.96 (0.93, 1.00) | 0.42 (0.15, 0.68) |
| Passing-Bablok | 249 | 0.961 | 1.00 (1.00, 1.06) | 0.20 (-0.27, 0.20) |
In this evaluation, human anticoagulated whole blood specimens tested ranged from 4.3 to 14.3 %A1c eq with the ARCHITECT™ Glycated Hemoglobin assay and from 4.4 to 14.5 %A1c with the Bio-Rad DIAMAT™ Glycosylated Hemoglobin Analyzer System.
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 864.7470 Glycosylated hemoglobin assay.
(a)
Identification. A glycosylated hemoglobin assay is a device used to measure the glycosylated hemoglobins (A1a , A1b , and A1c ) in a patient's blood by a column chromatographic procedure. Measurement of glycosylated hemoglobin is used to assess the level of control of a patient's diabetes and to determine the proper insulin dosage for a patient. Elevated levels of glycosylated hemoglobin indicate uncontrolled diabetes in a patient.(b)
Classification. Class II (performance standards).
0
510(k) Summarv Abbott ARCHITECTTM Glycated Hemoglobin
Summary of Safety and Effectiveness Information Supporting a Substantially Equivalent Determination
The following information as presented in the Premarket Notification [510(k)] for Abbott ARCHITECT™ Glycated Hemoglobin constitutes data supporting a substantially equivalent determination.
The ARCHITECT™ Glycated Hemoglobin assay is a Chemiluminescent Microparticle Immunoassay (CMIA) for the quantitative determination of glycated hemoglobin in human anticoagulated whole blood (EDTA, lithium heparin, or sodium heparin). The ARCHITECTTM Glycated Hemoglobin assay is calibrated with Abbott ARCHITECT™ Glycated Hemoglobin Calibrators. Abbott ARCHITECT™ Glycated Hemoglobin Controls are assayed for the verification of the accuracy and precision of the Abbott ARCHITECT™ i System.
Substantial equivalence has been demonstrated between the ARCHITECT™ Glycated Hemoglobin assay and the Bio-Rad DIAMAT™ Glycosylated Hemoglobin Analyzer System (K851636). The intended use of the ARCHITECTTM Glycated Hemoglobin assay is for the quantitative determination of glycated hemoglobin in human anticoagulated whole blood using a boronate affinity binding immunoassay. The intended use of the Bio-Rad DIAMAT™ Glycosylated Hemoglobin Analyzer System is for the quantitative determination of glycated hemoglobin in human anticoagulated whole blood using ion exchange high performance liquid chromatography (HPLC).
| Sample | Regression Method | n | r | Slope (95%CI) | Intercept (95% CI) |
|---|---|---|---|---|---|
| Whole Blood | Least Squares | 249 | 0.961 | 0.96 (0.93, 1.00) | 0.42 (0.15, 0.68) |
| Passing-Bablok | 249 | 0.961 | 1.00 (1.00, 1.06) | 0.20 (-0.27, 0.20) |
1
In this evaluation, human anticoagulated whole blood specimens tested ranged from 4.3 to 14.3 %A1c eq with the ARCHITECT™ Glycated Hemoglobin assay and from 4.4 to 14.5 %A1c with the Bio-Rad DIAMAT™ Glycosylated Hemoglobin Analyzer System.
In conclusion, these data demonstrate that the ARCHITECT™ Glycated Hemoglobin assay is as safe and effective as, and is substantially equivalent to, the Bio-Rad DIAMATTM Glycosylated Hemoglobin Analyzer System.
Prepared and Submitted April 27, 1999 by:
Katherine M. Wortley, Ph.D. Regulatory Specialist ADD Regulatory Affairs (847) 938-7707 Bldg. AP31, Dept. 9V6 Abbott Laboratories 200 Abbott Park Road Abbott Park, IL 60064-6200
2
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract symbol resembling an eagle or bird in flight, composed of three curved lines. The symbol is black and the background is white.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
NOV - 1 1999
Katherine M. Wortley, Ph.D. Regulatory specialist ADD Regulatory Affairs Abbott Laboratories Bldg. AP31. Dept. 9V6 200 Abbott Park Road Abbott Park, Illinois 60064-3537
K991483 Re:
Trade Name: Abbott ARCHITECT™ Glycated Hemoglobin Regulatory Class: II Product Code: LCP Dated: August 2, 1999 Received: August 3, 1999
Dear Dr. Wortley:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (OS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
3
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrl/dsma/dsmamain.html".
Sincerely yours,
Steven Sutman
Steven I. Gutman, M.D, M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
510(k) Number (if known): $991483 Device Name: Abbott ARCHITECT™ Glycated Hemoglobin
Indications For Use:
The Abbott ARCHITECT™ Glycated Hemoglobin assay is a boronate affinity binding assay intended to measure glycated hemoglobin in human anticoagulated whole blood. Measurement of glycated hemoglobin is used for the management of diabetes mellitus.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K991483
Prescription Use
(Per 21 CFR 801.109)
(Optional Format 1-2-96)
OR
Over-The-Counter Use__